Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/10/24
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor ConferencesGlobeNewsWire • 08/29/24
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/12/24
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/24
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment ChallengesGlobeNewsWire • 08/08/24
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 08/01/24
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024GlobeNewsWire • 07/18/24
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/10/24
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award WinnerGlobeNewsWire • 06/18/24
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/10/24
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for AcromegalyGlobeNewsWire • 06/03/24
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)GlobeNewsWire • 06/03/24
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference DataSeeking Alpha • 05/23/24
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking AbstractsGlobeNewsWire • 05/22/24
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/10/24
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024GlobeNewsWire • 05/02/24
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/11/24